Illumina, Inc. (NASDAQ:ILMN) Stake Increased by Russell Investments Group Ltd.

Russell Investments Group Ltd. raised its stake in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 78.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 69,646 shares of the life sciences company's stock after purchasing an additional 30,538 shares during the period. Russell Investments Group Ltd.'s holdings in Illumina were worth $9,725,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of ILMN. Vanguard Group Inc. increased its holdings in shares of Illumina by 15.0% in the 3rd quarter. Vanguard Group Inc. now owns 17,967,758 shares of the life sciences company's stock valued at $2,466,614,000 after acquiring an additional 2,336,935 shares during the last quarter. Polen Capital Management LLC increased its holdings in shares of Illumina by 0.6% in the 3rd quarter. Polen Capital Management LLC now owns 5,126,614 shares of the life sciences company's stock valued at $703,782,000 after acquiring an additional 29,153 shares during the last quarter. Loomis Sayles & Co. L P increased its holdings in shares of Illumina by 5.5% in the 3rd quarter. Loomis Sayles & Co. L P now owns 4,007,957 shares of the life sciences company's stock valued at $550,212,000 after acquiring an additional 208,267 shares during the last quarter. Barclays PLC increased its holdings in shares of Illumina by 120.0% in the 3rd quarter. Barclays PLC now owns 1,768,355 shares of the life sciences company's stock valued at $242,758,000 after acquiring an additional 964,709 shares during the last quarter. Finally, Ameriprise Financial Inc. increased its holdings in shares of Illumina by 13.6% in the 3rd quarter. Ameriprise Financial Inc. now owns 922,446 shares of the life sciences company's stock valued at $126,629,000 after acquiring an additional 110,138 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company's stock.

Analyst Ratings Changes

A number of research analysts recently issued reports on ILMN shares. Barclays raised their price target on Illumina from $85.00 to $100.00 and gave the stock an "underweight" rating in a research note on Wednesday, April 10th. Robert W. Baird raised their price target on Illumina from $125.00 to $128.00 and gave the stock a "neutral" rating in a research note on Friday. StockNews.com downgraded Illumina from a "buy" rating to a "hold" rating in a research note on Friday. Scotiabank dropped their price target on Illumina from $185.00 to $176.00 and set a "sector outperform" rating on the stock in a research note on Monday. Finally, HSBC downgraded Illumina from a "buy" rating to a "hold" rating in a research note on Tuesday, January 16th. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, Illumina currently has a consensus rating of "Hold" and an average price target of $164.65.

Insider Buying and Selling

In other news, CEO Jacob Thaysen acquired 7,330 shares of Illumina stock in a transaction that occurred on Thursday, February 22nd. The stock was purchased at an average cost of $135.29 per share, with a total value of $991,675.70. Following the completion of the acquisition, the chief executive officer now owns 14,861 shares in the company, valued at approximately $2,010,544.69. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.17% of the stock is currently owned by insiders.

Illumina Price Performance

Shares of ILMN traded down $6.16 during mid-day trading on Tuesday, hitting $112.82. The company's stock had a trading volume of 2,949,514 shares, compared to its average volume of 1,727,441. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.26. The firm has a 50-day simple moving average of $129.13 and a 200 day simple moving average of $126.95. The firm has a market capitalization of $17.97 billion, a P/E ratio of -13.84 and a beta of 1.20. Illumina, Inc. has a 1-year low of $89.00 and a 1-year high of $213.91.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its quarterly earnings results on Thursday, May 2nd. The life sciences company reported $0.09 EPS for the quarter, beating the consensus estimate of $0.04 by $0.05. The business had revenue of $1.08 billion during the quarter, compared to analysts' expectations of $1.05 billion. Illumina had a positive return on equity of 2.31% and a negative net margin of 28.71%. The company's quarterly revenue was down 1.0% compared to the same quarter last year. During the same period last year, the firm earned $0.08 EPS. Analysts predict that Illumina, Inc. will post 0.91 EPS for the current fiscal year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.